ZINPLAVA (bezlotoxumab), anti-toxin B monoclonal antibody of Clostridium difficile

• ZINPLAVA has Marketing Authorisation in the prevention of recurrent Clostridium difficile infection (CDI) in adults at high risk for recurrent CDI.
• Its efficacy has been demonstrated in combination with metronidazole and vancomycin.
• There is no robust efficacy data, in combination with fidaxomicin, or in more severe forms and/or with multiple recurrent infections (history of more than one episode of CDI). Its safety profile is overall satisfactory, with a reservation about use in patients with underlying congestive heart failure.

»  The therapeutic decision must be made with the assistance of an antibiotics specialist.